Pitcairn Co. Makes New Investment in Sanofi (NASDAQ:SNY)

Pitcairn Co. purchased a new stake in Sanofi (NASDAQ:SNY) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 5,627 shares of the company’s stock, valued at approximately $273,000.

Several other institutional investors have also made changes to their positions in SNY. Boston Partners lifted its position in shares of Sanofi by 1.9% during the 4th quarter. Boston Partners now owns 13,032,746 shares of the company’s stock valued at $648,617,000 after acquiring an additional 245,682 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Sanofi by 16.5% in the 1st quarter. Bank of New York Mellon Corp now owns 7,224,508 shares of the company’s stock valued at $351,111,000 after purchasing an additional 1,021,077 shares in the last quarter. Mondrian Investment Partners LTD grew its position in Sanofi by 43.1% in the first quarter. Mondrian Investment Partners LTD now owns 3,951,089 shares of the company’s stock valued at $192,023,000 after acquiring an additional 1,190,141 shares during the last quarter. Equity Investment Corp raised its stake in Sanofi by 23.0% during the first quarter. Equity Investment Corp now owns 2,393,474 shares of the company’s stock worth $116,323,000 after acquiring an additional 447,872 shares in the last quarter. Finally, Raymond James & Associates lifted its holdings in shares of Sanofi by 26.9% in the first quarter. Raymond James & Associates now owns 2,315,255 shares of the company’s stock worth $112,521,000 after acquiring an additional 491,498 shares during the last quarter. 10.04% of the stock is currently owned by institutional investors.

Sanofi Stock Performance

NASDAQ SNY opened at $53.10 on Friday. Sanofi has a fifty-two week low of $42.63 and a fifty-two week high of $55.72. The firm’s fifty day moving average price is $49.14 and its two-hundred day moving average price is $48.71. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.27. The stock has a market cap of $134.49 billion, a PE ratio of 26.68, a PEG ratio of 1.59 and a beta of 0.59.

Sanofi (NASDAQ:SNY) last issued its earnings results on Thursday, April 25th. The company reported $0.96 EPS for the quarter, hitting the consensus estimate of $0.96. The business had revenue of $11.36 billion during the quarter, compared to the consensus estimate of $11.75 billion. Sanofi had a return on equity of 26.25% and a net margin of 10.52%. On average, equities analysts expect that Sanofi will post 4.14 EPS for the current fiscal year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.